

The British MHRA Expected Many Vaccine Adverse Reactions in October 2020, Months Before the Vaccine Rollout Started

By [Real Science](#)

Global Research, March 29, 2022

[Real Science](#)

Region: [Europe](#)

Theme: [Intelligence](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#) and Twitter at [@crglobalization](#). Feel free to repost and share widely Global Research articles.

The British MHRA expected many vaccine adverse reactions, in October 2020, months before the vaccine rollout started. The Medicines and Healthcare Products Regulatory Agency (MHRA) issued a tender for “an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs).”

The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.

But they went ahead with the vaccine program anyway and passed it off as “Safe and Effective,” even though they knew it would cause serious harm.

The tender was issued by the MHRA Buyer Organisation and on 2 March 2022, it was still displayed on the European Union’s *Tenders Electronic Daily* (TED) [website](#). TED is a *Supplement to the Official Journal of the EU*.

Note that this is classified as an *extreme urgent request*.

For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.

Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.

Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.

Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.

The tender document has been stored in multiple places in case they try to erase this evidence by removing it from the tender website. [View or Download it here.](#)

The contract was awarded to the only applicant, Genpact (UK) for 1.5 million GBP.

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below

- The procurement falls outside the scope of application of the directive
For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool. Strictly necessary — it is not possible to retrofit the MHRA's legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.
Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.
Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.

IV.1.8) **Information about the Government Procurement Agreement (GPA)**
The procurement is covered by the Government Procurement Agreement: yes

Section V: Award of contract

V.2.2) **Information about tenders**
Number of tenders received: 1

V.2.3) **Name and address of the contractor**
Official name: Genpact (UK) Ltd
Town: London
NUTS code: UK UNITED KINGDOM
Country: United Kingdom
The contractor is an SME: no

V.2.4) **Information on value of the contract/lot (excluding VAT)**
Total value of the contract/lot: 1 500 000.00 GBP

Illustration by Good Sciening

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch_crg and Twitter at @crglobalization. Feel free to repost and share widely Global Research articles.

Featured image is from NaturalNews.com

The original source of this article is [Real Science](#)

Copyright © [Real Science](#), [Real Science](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca